Close Menu

PAM50

Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.

A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. 

The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test.

The finalized guidance follows a similar favorable LCD from Medicare contractor Palmetto, enabling reimbursement for Prosigna in a total of 39 US states.

The clinical practice guidelines include the PAM50 gene expression signature, which the Prosigna Assay is based on, as a predictive tool for chemotherapy benefit.

The decision follows a positive draft guidance from Palmetto GBA and several clinical care guidelines that acknowledge the validity of the test.

FDA cleared the test last year, and the updated labeling provides more information on the observed risk of distant recurrence five to 10 years after diagnosis. 

NEW YORK (GenomeWeb) – Researchers from NanoString Technologies and elsewhere have published a study in the Journal of Clinical Oncology showing that its PAM50-based Prosigna breast cancer test accurately predicts which patients with early stage, hormone receptor positive disease are at

With new publications and an expanding sales force, NanoString is ramping up its efforts to bolster adoption of its Prosigna breast cancer recurrence test.

NanoString Technologies this week announced the publication of a study in Clinical Cancer Research showing that the PAM50 assay, on which its Prosig

Pages

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.